Continuing weight-loss effect after topiramate discontinuation in obese persons with schizophrenia: A pilot open-label study

Pharmacopsychiatry

Volumn 47, Issue 4-5, 2014, Pages 162-168

  Liang, C S ^a,b   Yang, F W ^b   Huang, S Y ^a,b   Ho, P S ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

body weight; discontinuation; leptin; schizophrenia; topiramate

Indexed keywords

GLUCOSE; LEPTIN; TOPIRAMATE; ANTIOBESITY AGENT; FRUCTOSE;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INSULIN RESISTANCE; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; WEIGHT CHANGE; WEIGHT REDUCTION; ADULT; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; CLINICAL TRIAL; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; TIME;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; LEPTIN; MALE; MIDDLE AGED; OBESITY; SCHIZOPHRENIA; TIME FACTORS; WEIGHT LOSS;

EID: 84904789929     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1381984     Document Type: Article

References (40)

1. Silberstein S. D., Ben-Menachem E., Shank R. P. et al. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther: 2005; 27 154 165 (Pubitemid 40462008)
2. Verrotti A., Scaparrotta A., Agostinelli S. et al. Topiramate-induced weight loss: a review. Epilepsy Res: 2011; 95 189 199
3. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry: 2005; 4 5
4. Hahn M. K., Remington G., Bois D. et al. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol: 2010; 30 706 710
5. Rubio G., Ponce G., Jimenez-Arriero M. A. et al. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry: 2004; 37 37 40 (Pubitemid 38230738)
6. De Hert M. A., van Winkel R., Van Eyck D. et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res: 2006; 83 87 93
7. Sugawara N., Yasui-Furukori N., Sato Y. et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res: 2010; 123 244 250
8. Kahn R., Buse J., Ferrannini E. et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2005; 28 2289 2304 (Pubitemid 41242486)
9. Kim J. H., Yim S. J., Nam J. H. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res: 2006; 82 115 117 (Pubitemid 43202654)
10. Narula P. K., Rehan H. S., Unni K. E. et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res: 2010; 118 218 223
11. Ko Y. H., Joe S. H., Jung I. K. et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol: 2005; 28 169 175
12. Jarskog L. F., Hamer R. M., Catellier D. J. et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry: 2013; 170 1032 1040
13. Henderson D. C., Copeland P. M., Daley T. B. et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry: 2005; 162 954 962 (Pubitemid 40676209)
14. Chen C. H., Huang M. C., Kao C. F. et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry: 2013; 74 e424 e430
15. Khazaal Y., Zullino D. F. Rebound of weight gain following topiramate cessation. Pharmacopsychiatry: 2007; 40 85 86 (Pubitemid 46697683)
16. Bai Y. M., Lin C. C., Chen J. Y. et al. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry: 2011; 72 751 756
17. Matthews D. R., Hosker J. P., Rudenski A. S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: 1985; 28 412 419 (Pubitemid 15018832)
18. Blum W. F. Leptin: the voice of the adipose tissue. Horm Res Paediatr: 1997; 48 2 8 (Pubitemid 27464726)
19. Lingjaerde O., Ahlfors U. G., Bech P. et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand: 1987; 334 Suppl 1 100 (Pubitemid 17115352)
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry: 1960; 23 56 62
21. Gardner D. M., Murphy A. L., O'Donnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry: 2010; 167 686 693
22. Alberti K. G., Eckel R. H., Grundy S. M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation: 2009; 120 1640 1645
23. Myers M. G., Cowley M. A., Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol: 2008; 70 537 556 (Pubitemid 351738191)
24. Munzberg H., Bjornholm M., Bates S. H. et al. Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci: 2005; 62 642 652
25. Morris D. L., Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab: 2009; 297 E1247 E1259
26. Caricilli A. M., Penteado E., de Abreu L. L. et al. Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology: 2012; 153 4401 4411
27. Johnson B. A. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav: 2004; 29 1465 1479 (Pubitemid 39165999)
28. Heinz A., Siessmeier T., Wrase J. et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry: 2004; 161 1783 1789 (Pubitemid 39314671)
29. Wang G. J., Volkow N. D., Logan J. et al. Brain dopamine and obesity. Lancet: 2001; 357 354 357 (Pubitemid 32128542)
30. Wang G. J., Volkow N. D., Thanos P. K. et al. Imaging of brain dopamine pathways: implications for understanding obesity. J Addict Med: 2009; 3 8 18
31. Kenna G. A., Lomastro T. L., Schiesl A. et al. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev: 2009; 2 135 142
32. Arbaizar B., Diersen-Sotos T., Gomez-Acebo I. et al. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr: 2010; 38 8 12
33. Fruehwald-Schultes B., Oltmanns K. M., Toschek B. et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism: 2002; 51 531 536 (Pubitemid 34406574)
34. Kim Y. W., Kim J. Y., Park Y. H. et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes: 2006; 55 716 724
35. Aubert G., Mansuy V., Voirol M. J. et al. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism: 2011; 60 327 334
36. Karabacak I. Y., Karabacak O., Toruner F. B. et al. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. Gynecol Endocrinol: 2004; 19 196 201 (Pubitemid 40115917)
37. Baranowska B., Wolinska-Witort E., Martynska L. et al. Sibutramine therapy in obese women - effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol Lett: 2005; 26 675 679
38. Abo-Elmatty D. M., Zaitone S. A. Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. Eur Rev Med Pharmacol Sci: 2011; 15 1187 1195
39. Tschoner A., Engl J., Rettenbacher M. et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry: 2009; 42 29 34
40. de Lauzon B., Romon M., Deschamps V. et al. The Three-Factor Eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population. J Nutr: 2004; 134 2372 2380 (Pubitemid 39201611)